SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
OCUL
--
0.00%
--
Ocular Therapeutix to Present at the Jefferies Virtual Healthcare Conference
Business Wire · 6d ago
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 05/26 08:30
7 Perfect 10 Stocks to Buy Now
TipRanks · 05/25 15:00
Why Ocular Therapeutix Skyrocketed 19.3% Today
Motley Fool · 05/22 21:19
ZYNE, CLSN, SNCA and SNDX among midday movers
Seeking Alpha - Article · 05/22 16:40
Ocular Therapeutix prices stock offering at $5.50
Ocular Therapeutix (NASDAQ:OCUL) prices its public offering of ~8.2M common shares at $5.50 per share. Underwriters' over-allotment is an additional ~1.2M
seekingalpha · 05/20 16:54
Ocular Therapeutix Says Public Offering Of 8.18M Common Shares Priced At $5.50/Share
  BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and
Benzinga · 05/20 11:33
Ocular Therapeutix Announces Proposed Public Offering of Common Stock; Size Not Disclosed
Benzinga · 05/19 20:44
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public of
Business Wire · 05/19 20:44
Ocular Therapeutix: This Platform Technology Story Continues To Impress
Seeking Alpha - Article · 05/18 16:46
70 Biggest Movers From Friday
Gainers Sorrento Therapeutics, Inc (NASDAQ: SRNE) shares climbed 158% to close at $6.76 on Friday amid investor attention surrounding the company's STI-1499 coronavirus antibody.
Benzinga · 05/18 08:47
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Pha
Business Wire · 05/12 11:00
Ocular Therapeutix™ To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple presentations at the American Society of Catar
Business Wire · 05/11 11:00
H.C. Wainwright Sticks to Their Buy Rating for Ocular Therapeutix
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) on Monday, setting a price target of $10, which is approximately 67.50% above the present share price of $5.97.
Investing.com · 05/11 10:52
Edited Transcript of OCUL earnings conference call or presentation 8-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 05/09 06:42
Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/08 18:11
Ocular Therapeutix EPS misses by $0.04, beats on revenue
Ocular Therapeutix (NASDAQ:OCUL): Q1 GAAP EPS of -$0.41 misses by $0.04. Revenue of $2.61M (+432.7% Y/Y) beats by $0.25M. Press Release
seekingalpha · 05/08 16:01
Ocular Therapeutix: Q1 Earnings Insights
Benzinga · 05/08 13:43
Ocular Therapeutix: Q1 Earnings Insights
Shares of Ocular Therapeutix (NASDAQ:OCUL) were unchanged in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 8.89% year over year to ($0.41), which missed the estimate of ($0.37).
Benzinga · 05/08 12:43
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/08 12:25